PET/CT imaging as a measure of response in patients with advanced melanoma on immunotherapy plus hydroxychloroquine.
Not Recruiting
18-99 years
All
Phase
N/A
20 participants needed
1 Location
Brief description of study
The research study is a companion trial to the LIMIT Melanoma Trial, This study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on participants with advanced melanoma who are participating in the LIMIT Melanoma Trial. The imaging agent could help the doctor see where your CD8 T cells are located, which may help patients to determine likely response to treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
melanoma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older History of histologically confirmed melanoma as assessed per medical record review
Updated on
11 Sep 2024.
Study ID: 844867
